Perrigo Company plc (PRGO) 株式分析

企業概要

Perrigo Company plc is a prominent entity within the healthcare sector, specifically operating in the drug manufacturers - specialty & generic industry, where it delivers over-the-counter health and wellness solutions across the United States, Europe, and international markets. The company structures its operations through two primary segments, Consumer Self-Care Americas and Consumer Self-Care International, focusing on product categories such as upper respiratory solutions including cough suppressants. This enterprise maintains a significant operational footprint employing approximately 8,100 individuals to support its global manufacturing and distribution capabilities. With a market capitalization of $1.49B and annual revenue reaching $4.25B, Perrigo demonstrates the scale of a mid-cap player that commands substantial resources within the pharmaceutical supply chain. These valuation and revenue figures collectively indicate that the company holds a established position capable of sustaining large-scale production while navigating the complexities of global regulatory environments and supply chain logistics inherent to the specialty drug manufacturing landscape.

財務健全性

The company reported a revenue of $4.25B over the trailing twelve months, yet this top-line activity resulted in a net income of -$1,402,300,032, revealing a severe disconnect between sales generation and bottom-line profitability that points to substantial cost pressures or non-operating losses affecting the cost structure. Despite the negative net income, the firm generated positive EBITDA of $679.70M, suggesting that core operational cash generation remains intact even as accounting losses widen the gap between revenue and net profit. Free cash flow stood at $28.32M, which indicates a constrained but positive level of financial flexibility, allowing the company to cover essential obligations while retaining limited capacity for strategic investments or debt servicing. Profitability analysis highlights three distinct margin levels: a gross margin of 35.1% reflecting pricing power on products, an operating margin of 10.2% showing moderate efficiency before interest and taxes, and a profit margin of -33.5% illustrating the significant drag on overall earnings. The balance sheet presents a leveraged profile with cash holdings of $531.60M against total debt of $3.85B, resulting in a debt-to-equity ratio of 131.16% which signifies a highly leveraged capital structure reliant on creditor financing. Liquidity assessment via the current ratio of 2.76 suggests the company holds sufficient current assets to cover short-term liabilities, providing a buffer against immediate liquidity shocks despite the heavy debt load. Return on Equity is recorded at -38.7% while Return on Assets stands at 2.4%, metrics that reveal management is currently destroying shareholder value relative to equity while maintaining a marginal ability to generate returns on the total asset base.

バリュエーション評価

Valuation metrics show a trailing P/E ratio listed as N/A due to the negative earnings, whereas the forward P/E is 4.54, implying that the market prices the stock based on anticipated future profitability rather than current historical performance. The price-to-book ratio is 0.51, indicating that the market values the company at significantly less than its accounting book value, which often reflects a premium discount applied to firms with depressed earnings or high leverage. Alternative valuation measures include a price-to-sales ratio of 0.35 and an EV/EBITDA of 7.08, suggesting the stock is priced at a low multiple of its sales and adjusted earnings, potentially reflecting market skepticism regarding the sustainability of current cash flows or the depth of the earnings decline. Price action over the last year has ranged between a 52-week high of $28.44 and a 52-week low of $9.23, placing the current valuation within a broad historical band that captures both periods of expansion and contraction. The stock exhibits a beta of 0.49, which means its price volatility is roughly half that of the broader market, indicating lower sensitivity to general market swings compared to large-cap peers.

Growth & Income

Growth analysis indicates a revenue growth rate of -2.5% year-over-year, while earnings growth is listed as N/A due to the current negative earnings position, implying that the company is currently contracting in terms of top-line sales rather than expanding. Regarding income distribution, the company offers a dividend yield of 10.7% paired with a payout ratio of 10950.0%, a figure that is mathematically unsustainable given the negative net income and suggests the dividend is being funded from cash reserves or debt rather than current profits. This payout structure implies that the company is not reinvesting earnings into growth through dividends but is instead maintaining a high yield that may be vulnerable to cuts if cash reserves are depleted or earnings do not turn positive. Overall, the growth and income profile is characterized by declining revenue, negative profitability, and a high-yield dividend that lacks a sustainable earnings foundation, presenting a complex risk-reward dynamic for income-focused investors.